AstraZeneca

Vaccine
#AstraZeneca #Bioconjugates #Immunology / Virology & Vaccines #Mergers and acquisitions

AstraZeneca buys conjugate vaccine developer Omniose

Omniose is to be acquired by AstraZeneca, following a productive three-year exclusive research collaboration between the two companies.  Under the terms of the agreement, Omniose has become a wholly owned subsidiary of AstraZeneca and a part of the Infectious Disease Unit.   The acquisition brings Omniose’s… Read More

#Business & Investment #News

#ADME / Tox #Artificial intelligence (AI) #AstraZeneca #Collaboration #Drug safety #Tremont AI

Research collab will build AI solutions for accelerated safety screening

AstraZeneca and Tremont AI have announced a research collaboration to develop and evaluate AI solutions for accelerated safety screening in preclinical toxicologic pathology studies.  Assessing the safety of a new drug is one of the most demanding steps before it can reach patients.  Toxicologic pathologists… Read More

#News

#Artificial intelligence (AI) #AstraZeneca #Cardiometabolic diseases #Collaboration

AZ signs AI drug discovery deal with insitro

AstraZeneca and insitro have signed a worldwide exclusive research collaboration agreement to discover novel targets and therapeutics in metabolic dysfunction-associated steatohepatitis (MASH) and cardiomyopathies.   Under the terms of the agreement, insitro will receive $40 million upfront and up to approximately $1.46 billion in potential discovery, development, and… Read More

#Business & Investment #News

Lungs
#Asthma #AstraZeneca #European Commission #European Medicines Agency

EC approves first triple-combination therapy for asthma maintenance

AstraZeneca’s fixed-dose triple-combination Trixeo Aerosphere (budesonide/glycopyrronium/formoterol fumarate dihydrate or BGF) has been approved in the European Union (EU) as a maintenance treatment for asthma.  It is approved in patients 12 years of age and older who are not adequately controlled by a combination of a medium dose… Read More

#News #Regulatory

Asthma inhaler
#Asthma #AstraZeneca #Committee for Medicinal Products for Human Use #European Medicines Agency

Asthma drug Trixeo recommended for approval in the EU

AstraZeneca’s fixed-dose triple-combination Trixeo Aerosphere (budesonide/glycopyrronium/formoterol fumarate or BGF) has been recommended for approval in the EU for the maintenance treatment of asthma in patients 12 years of age and older.  It is recommended in patients who are not adequately controlled by a combination of a medium… Read More

#News #Regulatory

#AI #AstraZeneca #Drug discovery #Isomorphic Labs #Pistoia Alliance

From the Editor: The steady shift to AI

It is especially difficult within the life sciences sector – and indeed everyday life – to avoid mentions of AI and the inevitable changes it will bring, and is bringing, to drug discovery.   Further difficulty stems from the need to distinguish between hype, reality and fantasy. Drug discovery and… Read More

#Exclusive Content

#AstraZeneca #Drug discovery #Life sciences #o2h #o2h Discovery #o2h Group #o2h Ventures

CWOW and the future of integrated drug discovery

Held from 11–19 June 2026, CWOW welcomed more than 5,000 attendees across 37 venues, delivering over 280 sessions and bringing together investors, entrepreneurs, academics, policymakers, operators, local communities and the wider biotech and techbio community from across the UK and beyond. Read more about the event here. Below, DDW… Read More

#Exclusive Content

#AstraZeneca #Drug discovery #Europe #European Federation of Pharmaceutical Industries and Associations #FDA #Francis Crick Institute #Hypertension #Lung cancer #Mental health #Tropical disease #University of Dundee #Wellcome Trust

DDW Highlights: 26 May 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, a report showed patients in Europe face barriers to medicine access. Elsewhere,… Read More

#Podcasts

FDA headquarters
#AstraZeneca #FDA #Hypertension

FDA approves hypertension treatment in landmark step

The US Food and Drug Administration (FDA) has approved AstraZeneca’s Baxfendy (baxdrostat) in the US for the treatment of hypertension.  Baxfendy has been approved as a first-in-class aldosterone synthase inhibitor (ASI) for the treatment of hypertension in combination with other antihypertensive medications, to lower blood pressure in adults who are not… Read More

#News #Regulatory

#Artificial intelligence (AI) #AstraZeneca #Collaboration #Immunai #Oncology

AstraZeneca expands AI oncology collaboration with Immunai

AstraZeneca and Immunai have expanded their collaboration, extending a multi-year collaboration in oncology clinical development through 2027.  Under the new deal, Immunai is eligible to receive up to $37.5 million over 2026-2027. It marks the third expansion of the partnership between the two companies, building on previous… Read More

#Business & Investment #News

#AstraZeneca #BioIndustry Association #Biotech #Boehringer Ingelheim #FDA #Gene therapy #Genetics #Hearing Loss #HIV #Investment #Malaria #Novartis #UK #WHO

DDW Highlights: 6 May 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, the UK made headlines for both the investment it has attracted and… Read More

#Podcasts

#AstraZeneca #BioIndustry Association #Biotech #Boehringer Ingelheim #FDA #Gene therapy #Genetics #Hearing Loss #HIV #Investment #Malaria #Novartis #UK #WHO

This week in Drug Discovery (27 April – 1 May) 

News round-up for 27 April – 1 May by Bruno Quinney, Content Team at DDW.  This week, the UK has made headlines for both the investment it has attracted and the clinical trial reforms it has rolled out. Elsewhere, the world’s first antimalarial drug for newborns could soon address a critical unmet… Read More

#News

Woman using an asthma inhaler
#Asthma #AstraZeneca #FDA

FDA approves first asthma triple therapy in US

The US Food and Drug Administration (FDA) has approved the first and only triple therapy for patients 12 years and older with asthma.  AstraZeneca’s fixed-dose triple-combination therapy Breztri Aerosphere has been approved in the US for the maintenance treatment of asthma in adult and paediatric patients 12 years of age… Read More

#News #Regulatory

UK
#ABPI #AstraZeneca #Life sciences #UK

AstraZeneca investment strengthens UK’s position, CEO says 

AstraZeneca’s investment U-turn shows the UK is “a global destination for life sciences investment”, the ABPI’s Chief Executive has said.  Richard Torbett was speaking after AstraZeneca announced it would resume large-scale activity in the UK with a £300 million ($405 million) investment. The drugmaker had previously rolled back… Read More

#Business & Investment #News

Drug manufacturing
#AstraZeneca #England #Hyperkalaemia #Wales

Access to hyperkalaemia drug expands across England and Wales 

Access to AstraZeneca’s hyperkalaemia treatment Lokelma has been expanded across England and Wales.  AstraZeneca announced the National Institute for Health and Care Excellence (NICE) had issued a draft recommendation for lokelma (sodium zirconium cyclosilicate). Under the new willingness-to-pay threshold, more than double the number of patients could… Read More

#News #Regulatory